XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 3 Months Ended
Mar. 31, 2023
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
March 31,
20232022
Revenue related to Novartis agreement:
Recognition of upfront license fee$7,696 $7,018 
Research services2,059 1,877 
Total$9,755 $8,895 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
March 31,
20232022
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$130,630 $7,306 
Cost-sharing payments for research services, net variable consideration1,672 3,887 
Total$132,302 $11,193 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
March 31,
20232022
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$11,440 $6,159 
Research services variable consideration868 149 
Total$12,308 $6,308 
Sanofi S.A.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):
Three Months Ended
March 31,
20232022
Revenue related to Sanofi agreement:
Recognition of upfront fee$— $311 
Research services— 978 
Milestone achievement— 210 
Total$— $1,499